Abdel-Azeez Hala A, Elhady Hoda A, Fikry Abeer A
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Gastroenterol Hepatol Bed Bench. 2022 Spring;15(2):139-145.
The current study purposed to evaluate serum COMP (Cartilage oligomeric matrix protein) as a diagnostic marker for HCC in patients with cirrhosis and to correlate it with other parameters of disease progression.
COMP is known to promote fibrosis in various tissues. Emerging evidence shows that COMP plays critical roles in tumor development. It can serve as a fibrosis and cancer biomarkers.
The study included 24 subjects who serve as the healthy control, 24 cirrhotic patients without HCC, and 24 HCC patients with cirrhosis. All participants were subjected to liver function tests, AFP, calculation of fibrotic indices (APRI and FIB-4), and serum COMP by ELISA.
COMP was significantly increased in cirrhotic patients when compared to healthy controls and in HCC patients when compared to cirrhotic patients and healthy controls. A significant positive correlation was observed between COMP and APRI and FIB-4 in cirrhotic and HCC patients. Based on receiver operating characteristic (ROC) curve analysis, COMP had an rea under curve (AUC) of 0.943 with 87.5% sensitivity and 79.2% specificity for diagnosis of HCC in cirrhotic patients. In combination with AFP, the sensitivity was increased to 100%.
COMP might act as a promising non-invasive biomarker for HCC either alone or in combination with AFP. It was correlated with the degree of fibrosis and associated with advanced cancer staging.
本研究旨在评估血清软骨寡聚基质蛋白（COMP）作为肝硬化患者肝癌诊断标志物的价值，并将其与疾病进展的其他参数进行关联。
已知COMP可促进多种组织的纤维化。新出现的证据表明，COMP在肿瘤发展中起关键作用。它可作为纤维化和癌症的生物标志物。
该研究纳入24名健康对照者、24名无肝癌的肝硬化患者以及24名合并肝硬化的肝癌患者。所有参与者均接受肝功能检查、甲胎蛋白检测、纤维化指标（APRI和FIB-4）计算以及通过酶联免疫吸附测定法检测血清COMP。
与健康对照者相比，肝硬化患者的COMP显著升高；与肝硬化患者及健康对照者相比，肝癌患者的COMP也显著升高。在肝硬化和肝癌患者中，COMP与APRI及FIB-4之间存在显著正相关。基于受试者工作特征（ROC）曲线分析，COMP诊断肝硬化患者肝癌的曲线下面积（AUC）为0.943，灵敏度为8�.5%，特异度为79.2%。与甲胎蛋白联合使用时，灵敏度提高到100%。
COMP单独或与甲胎蛋白联合使用时，可能是一种有前景的肝癌非侵入性生物标志物。它与纤维化程度相关，并与癌症晚期分期有关。
